HomeCompareAXDX vs JEPQ

AXDX vs JEPQ: Dividend Comparison 2026

AXDX yields 5882.35% · JEPQ yields 11.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AXDX wins by $302684608132120.00M in total portfolio value
10 years
AXDX
AXDX
● Live price
5882.35%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$302684608132120.06M
Annual income
$292,889,908,842,934,530,000.00
Full AXDX calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.10%
Share price
$55.52
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.8K
Annual income
$2,152.59
Full JEPQ calculator →

Portfolio growth — AXDX vs JEPQ

📍 AXDX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAXDXJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AXDX + JEPQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AXDX pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AXDX
Annual income on $10K today (after 15% tax)
$500,000.00/yr
After 10yr DRIP, annual income (after tax)
$248,956,422,516,494,340,000.00/yr
JEPQ
Annual income on $10K today (after 15% tax)
$943.83/yr
After 10yr DRIP, annual income (after tax)
$1,829.70/yr
At 15% tax rate, AXDX beats the other by $248,956,422,516,494,340,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AXDX + JEPQ for your $10,000?

AXDX: 50%JEPQ: 50%
100% JEPQ50/50100% AXDX
Portfolio after 10yr
$151342304066060.06M
Annual income
$146,444,954,421,467,270,000.00/yr
Blended yield
96.76%
📊

Analyst Conviction Gap

Where Wall Street is split right now

AXDX
Analyst Ratings
1
Buy
2
Hold
1
Sell
Consensus: Hold
Altman Z
-39.5
Piotroski
2/9
JEPQ
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AXDX buys
0
JEPQ buys
0
No recent congressional trades found for AXDX or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAXDXJEPQ
Forward yield5882.35%11.10%
Annual dividend / share$2.00$6.16
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$302684608132120.06M$44.8K
Annual income after 10y$292,889,908,842,934,530,000.00$2,152.59
Total dividends collected$302025190529273.63M$16.3K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: AXDX vs JEPQ ($10,000, DRIP)

YearAXDX PortfolioAXDX Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$598,935$588,235.29$11,930$1,110.39+$587.0KAXDX
2$33,567,485$32,926,624.20$14,133$1,224.34+$33.55MAXDX
3$1,760,572,584$1,724,655,375.00$16,632$1,340.46+$1760.56MAXDX
4$86,422,145,745$84,538,333,079.89$19,454$1,457.97+$86422.13MAXDX
5$3,970,768,237,328$3,878,296,541,381.34$22,626$1,576.08+$3970768.21MAXDX
6$170,784,185,257,923$166,535,463,243,981.50$26,175$1,694.09+$170784185.23MAXDX
7$6,876,898,713,370,412$6,694,159,635,144,434.00$30,133$1,811.32+$6876898713.34MAXDX
8$259,275,158,018,476,900$251,916,876,395,170,560.00$34,531$1,927.17+$259275158018.44MAXDX
9$9,153,924,569,332,272,000$8,876,500,150,252,502,000.00$39,403$2,041.08+$9153924569332.23MAXDX
10$302,684,608,132,120,050,000$292,889,908,842,934,530,000.00$44,787$2,152.59+$302684608132120.00MAXDX

AXDX vs JEPQ: Complete Analysis 2026

AXDXStock

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Full AXDX Calculator →

JEPQETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this AXDX vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AXDX vs SCHDAXDX vs JEPIAXDX vs OAXDX vs KOAXDX vs MAINAXDX vs XYLDAXDX vs QYLDAXDX vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.